Sally C. M. Lau

Also affiliated with Princess Margaret Cancer Centre, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors”.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy

Nature Immunology(2022)10.1038/s41590-022-01262-7

N/A

0.596DataRank · unranked

52 citations

Ramy Gadalla, Heidi Elsaesser, Diala Abd-Rabbo, Rene Quevedo, S.Y. Cindy Yang +19 more

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.18.537350

N/A

0.104DataRank · unranked

1 citations

David H. Peng, David Fenyö, Hao Yuan, Alfonso Lopez, Daniel Levin +26 more